Vericel (NASDAQ:VCEL) PT Raised to $55.00

Vericel (NASDAQ:VCEL) had its price objective hoisted by HC Wainwright from $53.00 to $55.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 13.05% from the company’s current price.

Several other research analysts have also recently weighed in on VCEL. TheStreet raised Vericel from a “d+” rating to a “c-” rating in a report on Monday, January 29th. Truist Financial reissued a “buy” rating and issued a $54.00 price objective on shares of Vericel in a research note on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Vericel presently has a consensus rating of “Moderate Buy” and an average target price of $46.80.

Vericel Stock Up 2.0 %

VCEL stock traded up $0.96 during trading on Thursday, reaching $48.65. 318,992 shares of the company’s stock were exchanged, compared to its average volume of 524,091. Vericel has a 1-year low of $30.18 and a 1-year high of $53.05. The company’s fifty day moving average price is $47.24 and its 200-day moving average price is $41.61. The firm has a market cap of $2.35 billion, a PE ratio of -540.56 and a beta of 1.74.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Vericel had a negative net margin of 1.61% and a negative return on equity of 1.55%. The company had revenue of $51.28 million for the quarter, compared to the consensus estimate of $49.07 million. During the same period in the previous year, the firm earned ($0.16) EPS. Vericel’s revenue was up 25.0% on a year-over-year basis. As a group, sell-side analysts expect that Vericel will post 0.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vericel news, SVP Sean C. Flynn sold 8,115 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $45.33, for a total value of $367,852.95. Following the sale, the senior vice president now owns 167 shares of the company’s stock, valued at approximately $7,570.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Vericel news, SVP Sean C. Flynn sold 8,115 shares of Vericel stock in a transaction on Friday, March 8th. The shares were sold at an average price of $45.33, for a total transaction of $367,852.95. Following the sale, the senior vice president now owns 167 shares in the company, valued at $7,570.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert L. Md Zerbe sold 3,278 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total transaction of $169,046.46. Following the sale, the director now directly owns 23,395 shares in the company, valued at approximately $1,206,480.15. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,267 shares of company stock valued at $2,450,996. Insiders own 7.20% of the company’s stock.

Institutional Trading of Vericel

Hedge funds and other institutional investors have recently made changes to their positions in the business. MCF Advisors LLC increased its stake in shares of Vericel by 86.1% during the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 223 shares during the last quarter. Arcadia Investment Management Corp MI bought a new position in Vericel in the 1st quarter valued at about $27,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Vericel in the fourth quarter valued at approximately $33,000. GAMMA Investing LLC bought a new position in Vericel during the fourth quarter worth about $65,000. Finally, RiverPark Advisors LLC acquired a new stake in Vericel during the first quarter worth approximately $147,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.